Rojas-Rivera Diego, Delvaeye Tinneke, Roelandt Ria, Nerinckx Wim, Augustyns Koen, Vandenabeele Peter, Bertrand Mathieu J M
Inflammation Research Center, VIB, Technologiepark 927, Zwijnaarde-Ghent 9052, Belgium.
Department of Biomedical Molecular Biology, Ghent University, Technologiepark 927, Zwijnaarde-Ghent 9052, Belgium.
Cell Death Differ. 2017 Jun;24(6):1100-1110. doi: 10.1038/cdd.2017.58. Epub 2017 Apr 28.
Accumulation of unfolded proteins in the endoplasmic reticulum (ER) causes a state of cellular stress known as ER stress. The cells respond to ER stress by activating the unfolded protein response (UPR), a signaling network emerging from the ER-anchored receptors IRE1α, PERK and ATF6. The UPR aims at restoring ER protein-folding homeostasis, but turns into a toxic signal when the stress is too severe or prolonged. Recent studies have demonstrated links between the UPR and inflammation. Consequently, small molecule inhibitors of IRE1α and PERK have become attractive tools for the potential therapeutic manipulation of the UPR in inflammatory conditions. TNF is a master pro-inflammatory cytokine that drives inflammation either directly by promoting gene activation, or indirectly by inducing RIPK1 kinase-dependent cell death, in the form of apoptosis or necroptosis. To evaluate the potential contribution of the UPR to TNF-induced cell death, we tested the effects of two commonly used PERK inhibitors, GSK2606414 and GSK2656157. Surprisingly, we observed that both compounds completely repressed TNF-mediated RIPK1 kinase-dependent death, but found that this effect was independent of PERK inactivation. Indeed, these two compounds turned out to be direct RIPK1 inhibitors, with comparable potency to the recently developed RIPK1 inhibitor GSK'963 (about 100 times more potent than NEC-1s). Importantly, these compounds completely inhibited TNF-mediated RIPK1-dependent cell death at a concentration that did not affect PERK activity in cells. In vivo, GSK2656157 administration protected mice from lethal doses of TNF independently of PERK inhibition and as efficiently as GSK'963. Together, our results not only report on new and very potent RIPK1 inhibitors but also highlight the risk of misinterpretation when using these two PERK inhibitors in the context of ER stress, cell death and inflammation.
内质网(ER)中未折叠蛋白的积累会引发一种称为内质网应激的细胞应激状态。细胞通过激活未折叠蛋白反应(UPR)来应对内质网应激,UPR是一种从内质网锚定受体IRE1α、PERK和ATF6产生的信号网络。UPR旨在恢复内质网蛋白折叠的稳态,但当应激过于严重或持续时间过长时,它会转变为一种毒性信号。最近的研究表明UPR与炎症之间存在联系。因此,IRE1α和PERK的小分子抑制剂已成为在炎症条件下潜在治疗性调控UPR的有吸引力的工具。肿瘤坏死因子(TNF)是一种主要的促炎细胞因子,它通过促进基因激活直接驱动炎症,或者通过诱导RIPK1激酶依赖性细胞死亡(以凋亡或坏死性凋亡的形式)间接驱动炎症。为了评估UPR对TNF诱导的细胞死亡的潜在作用,我们测试了两种常用的PERK抑制剂GSK2606414和GSK2656157的效果。令人惊讶的是,我们观察到这两种化合物都完全抑制了TNF介导的RIPK1激酶依赖性死亡,但发现这种作用与PERK失活无关。事实上,这两种化合物原来是直接的RIPK1抑制剂,其效力与最近开发的RIPK1抑制剂GSK'963相当(比NEC-1s强约100倍)。重要的是,这些化合物在不影响细胞中PERK活性的浓度下完全抑制了TNF介导的RIPK1依赖性细胞死亡。在体内,给予GSK2656157可保护小鼠免受致死剂量的TNF的影响,且与GSK'963一样有效,与PERK抑制无关。总之,我们的结果不仅报道了新的且非常有效的RIPK1抑制剂,还强调了在应激、细胞死亡和炎症的背景下使用这两种PERK抑制剂时可能出现错误解读的风险。